Hypertension in Pregnancy (Part 1): Blood Pressure Targets, Aspirin Prophylaxis, and Antihypertensive Therapy

Key Takeaways

• Treatment thresholds vary according to clinical phenotype, and consensus among guidelines remains incomplete. In chronic hypertension, North American practice has embraced initiating or maintaining therapy at 140/90 mm Hg. In gestational hypertension and preeclampsia without severe features, however, the American College of Obstetricians and Gynecologists (ACOG) reserves oral therapy for blood pressures of 160/110 mm Hg or higher. In contrast, the ISSHP and NICE initiate treatment at a threshold of 140/90 mm Hg, targeting a diastolic blood pressure of approximately 85 mm Hg.
• The preeclampsia cascade is triggered by defective spiral artery remodeling and placental malperfusion. Syncytiotrophoblast stress leads to the release of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, which sequester placental growth factor (PlGF) and VEGF, disrupting TGF-beta signaling in the maternal endothelium. A predominance of thromboxane A2 over prostacyclin serves as the principal therapeutic target of low-dose aspirin, which irreversibly acetylates the platelet COX-1 enzyme.
• Aspirin therapy should be recommended in the presence of one high-risk factor or two or more moderate-risk factors. Treatment should be initiated between 12 and 16 weeks of gestation and taken at bedtime. Although the US standard remains 81 mg/day, doses of 150 to 162 mg/day appear likely superior to 81 mg/day for the prevention of preterm preeclampsia. The drug should be discontinued at 36 weeks or at delivery, depending on the protocol used.
• First-line oral antihypertensive agents are labetalol (100 mg twice daily, maximum 2400 mg/day) and extended-release nifedipine (30 mg daily, maximum 120 mg/day). Methyldopa represents an acceptable alternative. Conversely, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, mineralocorticoid receptor antagonists, and atenolol are strictly contraindicated.
• Severe-range blood pressure of 160/110 mm Hg or higher persisting for at least 15 minutes warrants urgent intervention within 30 to 60 minutes. Because late-onset postpartum preeclampsia cases frequently present with headache within the first 10 days, blood pressure must be assessed in the hospital or post-discharge within the first 72 hours postpartum in women with severe hypertension, and evaluation should be repeated on postpartum days 7 to 10 across all hypertensive pregnancies.

Introduction and Clinical Background

Hypertensive disorders of pregnancy represent one of the rare clinical scenarios in which an internist, an obstetrician-gynecologist, and a neonatologist may confront the identical blood pressure measurement, yet each operates from a distinctly different calculus of risk. The maternal cardiovascular system undergoes its most demanding physiological stress test of adulthood during gestation. Plasma volume expands by approximately 40% to 50%, cardiac output increases by 30% to 50%, and systemic vascular resistance falls markedly during the first and second trimesters. Failure of these adaptive mechanisms, or a preexisting vascular insult secondary to chronic hypertension, obesity, diabetes, or renal disease, unleashes a broad spectrum of disease ranging from benign gestational hypertension to eclampsia, HELLP syndrome, placental abruption, and maternal stroke.

The epidemiological burden is substantial and markedly disparate. In its recommendation statement, the US Preventive Services Task Force (USPSTF) noted that preeclampsia affects approximately 4% of pregnancies in the United States and represents the second leading cause of maternal mortality worldwide. The Task Force further highlighted that case-fatality rates from preeclampsia are three times higher among African American women than among White women, issuing a Grade B recommendation for blood pressure screening throughout pregnancy^[1]. This disparity reflects differences in the prevalence of underlying risk factors, access to prenatal care, and the promptness of treatment escalation when severe-range blood pressures are identified; it is therefore as much a consequence of clinical systems as it is of biology.

In clinical practice, the principal diagnostic and therapeutic pitfalls directly affecting maternal and fetal prognosis include the following:

• Undiagnosed chronic hypertension. Because many reproductive-aged women do not undergo routine blood pressure monitoring, it frequently goes unrecognized prior to conception. The physiological drop in blood pressure seen in the second trimester can mask the condition and lead to misclassification as gestational hypertension.
• Delayed aspirin prophylaxis. Aspirin is frequently initiated after the window of maximal placental benefit has closed, or it is never offered to women with combinations of moderate-risk factors.
• The postpartum period. This period remains a perilous blind spot. Although definitions vary, postpartum preeclampsia must be considered in women with new-onset hypertension between 48 hours and 6 weeks after delivery. The majority of late-onset cases present within the first 7 to 10 days, most commonly with neurological symptoms (typically headache)^[2]. Because many women have already been discharged from obstetric follow-up by this point, they present initially to emergency physicians, internists, or general practitioners.

The historical context of this topic is equally important. For decades, obstetric practice was governed by the concern that lowering maternal blood pressure would compromise uteroplacental perfusion and fetal growth. This apprehension was reinforced by early meta-regression analyses correlating the magnitude of reduction in mean arterial pressure with lower birth weight. Consequently, a permissive approach to non-severe hypertension was widely adopted, one that has only recently been challenged by emerging randomized trial evidence in chronic hypertension. This first installment of the review addresses target blood pressure levels, prophylaxis protocols, and pharmacotherapy; long-term cardiovascular and renal sequelae will be detailed in Part 2 of the series.

Molecular and Pathophysiological Mechanisms

Defective Placentation and the Antiangiogenic Milieu

The prevailing model of early-onset preeclampsia comprises two stages:

• Stage one: defective placentation. During the first half of pregnancy, extravillous cytotrophoblasts inadequately invade the decidua and inner myometrium. Consequently, rather than transforming into high-capacitance, low-resistance conduits, the spiral arteries retain their muscular coat and vasoreactive properties. This results in intermittent, high-velocity perfusion within the intervillous space, triggering ischemia-reperfusion injury, oxidative stress, and endoplasmic reticulum stress in the syncytiotrophoblast.
• Stage two: maternal syndrome. The stressed placenta secretes soluble fms-like tyrosine kinase-1 (sFlt-1), a truncated VEGF receptor that binds and neutralizes circulating placental growth factor (PlGF) and VEGF. The placenta also sheds soluble endoglin, which blocks TGF-beta1 signaling mediated by endothelial endoglin and endothelial nitric oxide synthase.

Loss of tonic VEGF signaling has direct consequences in fenestrated endothelia, such as the glomerulus, hepatic sinusoids, and choroid plexus:

• glomerular endotheliosis and proteinuria;
• hepatocellular injury;
• posterior reversible encephalopathy.

Superimposed on this is a pressor state driven by multiple mechanisms:

• decreased nitric oxide bioavailability;
• increased endothelin-1 production;
• agonistic autoantibodies directed against the angiotensin II type 1 receptor;
• marked angiotensin II sensitivity, contrasting sharply with the relative angiotensin refractoriness of normal pregnancy.

Late-onset preeclampsia arising after 34 weeks of gestation reflects a different balance. Rather than defective invasion, it is the result of maternal cardiometabolic burden acting on a placenta that has outgrown its perfusion reserve. This distinction explains why prophylactic interventions directly targeting placentation, foremost among them aspirin, are substantially more effective in preterm preeclampsia than in term disease.

Thromboxane and Prostacyclin Imbalance: The Pharmacological Target of Aspirin

Placental ischemia skews the eicosanoid balance toward platelet-derived thromboxane A2, a vasoconstrictor and platelet agonist. Concurrently, endothelial- and trophoblast-derived prostacyclin production—a vasodilator and antiaggregant—is reduced. Aspirin irreversibly acetylates a serine residue within the cyclooxygenase channel of COX-1. Because anucleate platelets cannot resynthesize the enzyme, their thromboxane production is suppressed for the lifespan of the platelet, whereas nucleated endothelial cells regenerate COX activity within several hours.

The argument favoring higher-dose prophylaxis relies on this selective inhibition of COX-1, which suppresses thromboxane A2 synthesis while sparing prostacyclin. Proponents of this strategy point to three core observations:

• a dose-response relationship showing that doses of 100 mg or greater are more effective than lower doses;
• preserved COX-1 pharmacological selectivity even at a dose of 162 mg;
• aspirin resistance associated with altered pharmacokinetics in pregnancy or obesity, which can be overcome with 162 mg^[3].

Pregnancy expands plasma volume and increases renal clearance and esterase activity, thereby lowering systemic salicylate exposure. Obesity leads to an increased volume of distribution and accelerated platelet turnover. These factors represent plausible mechanisms for the incomplete platelet inhibition observed at the 81 mg dose in patients with high body weight.

The effect of aspirin is likely not restricted to platelets alone. Although its precise characteristics in humans remain incompletely understood, it also exerts effects on trophoblast invasion, the sFlt-1/PlGF balance, and inflammatory signaling pathways.

Mitochondrial Dysfunction and Oxidative Stress in Trophoblasts

Mitochondrial damage is increasingly recognized as a proximal amplifier of placental oxidative stress. In an in vitro model utilizing first-trimester ACH-3P trophoblasts, researchers recapitulated preeclampsia-like stimuli via three injury mechanisms:

• HIF-1alpha activation;
• direct mitochondrial toxicity;
• TNF-alpha exposure.

These stimuli reduced mitochondrial size, increased mitochondrial circularity, and decreased the number of mitochondria per cell. The tested therapies demonstrated condition-specific effects:

• Metformin restored mitochondrial architecture under inflammatory stress and normalized mfn1 and atg5 expression.
• Aspirin corrected mitochondrial morphology under hypoxic conditions and reduced oxygen consumption (p value < 0.01)^[4].

These are cell-culture observations obtained at supratherapeutic concentrations. While generating hypotheses regarding pleiotropic drug effects, they do not prove clinical benefit in humans. Nevertheless, these findings provide a promising area of investigation within the framework of drug repurposing.

Maternal Hemodynamic Phenotypes

Blood pressure is the product of cardiac output and systemic vascular resistance, and hypertensive pregnancies are not hemodynamically uniform. Maternal cardiac function has been compared across gestational hypertension, mild and severe preeclampsia, and normal pregnancy^[5]. Clinically, two broad profiles are described:

• a hyperdynamic, high-output, low-resistance state, typical of late-onset disease and maternal obesity;
• a low-output, high-resistance state with impaired diastolic function, typical of early-onset preeclampsia, particularly when accompanied by fetal growth restriction.

These physiological distinctions form the foundation for theoretical approaches toward targeted treatment of maternal hemodynamic adaptations and the prevention of recurrent preeclampsia. In practice, this concept seeks to match the therapeutic agent to the hemodynamic phenotype: selecting a beta-blocker for the hyperdynamic profile and a vasodilator for the high-resistance profile; however, this strategy remains an investigational area not yet formally endorsed by guidelines.

Pharmacological Targets of Antihypertensives Used in Pregnancy

Pregnancy-compatible antihypertensives act via distinct targets, each carrying unique clinical trade-offs:

• Labetalol combines nonselective beta-adrenergic blockade with alpha1 antagonism in a beta-to-alpha ratio of approximately 3:1 orally and 7:1 intravenously. It lowers vascular resistance without inducing the reflex tachycardia seen with pure vasodilators. Pure beta1-selective blockade with atenolol is avoided due to its association with fetal growth restriction.
• Nifedipine, a dihydropyridine calcium channel blocker targeting L-type voltage-gated channels, produces arteriolar vasodilation and modest natriuresis. It is the agent of choice in the high-resistance phenotype and in women with asthma, for whom labetalol is relatively contraindicated.
• Methyldopa is converted to alpha-methylnorepinephrine, a false neurotransmitter that stimulates central alpha2 receptors to reduce sympathetic outflow. Although it possesses the longest pediatric follow-up data among these agents, its utility is limited by sedation, hepatotoxicity, and postpartum depressive symptoms.
• Hydralazine opens potassium channels and inhibits inositol trisphosphate-mediated calcium release in arteriolar smooth muscle. It is used intravenously for acute blood pressure control and orally only as adjunctive therapy.

The renin-angiotensin-aldosterone system must be avoided at every step:

• ACE inhibitors, angiotensin receptor blockers, and direct renin inhibitors such as aliskiren are fetotoxic in the second and third trimesters. Angiotensin II is strictly required for fetal renal perfusion and tubular development; exposure to these agents leads to oligohydramnios, renal tubular dysgenesis, calvarial hypoplasia, and neonatal anuria.
• Steroidal mineralocorticoid receptor antagonists, such as spironolactone, carry a risk of antiandrogenic effects on male fetal genital development. Eplerenone lacks these antiandrogenic effects, but data regarding its use in pregnancy are extremely limited.
• The nonsteroidal antagonist finerenone and the aldosterone synthase inhibitors baxdrostat and lorundrostat have no human pregnancy data. These agents must be considered contraindicated.

Magnesium sulfate is not an antihypertensive. It prevents eclamptic seizures through neuromuscular and vascular calcium antagonism, N-methyl-D-aspartate receptor antagonism, and cerebral vasodilation that relieves vasospasm.

Clinical Evidence and Guideline Comparison

Chronic Hypertension: Evidence from CHAP and CHIPS

The randomized evidence reshaping treatment targets in chronic hypertension stems from two research programs: the Chronic Hypertension and Pregnancy (CHAP) project and the Control of Hypertension in Pregnancy Study (CHIPS). Both trials have been evaluated together in extended analyses regarding the impact of blood pressure control on maternal and fetal outcomes^[6]. Although the individual hazard ratios and numerical event rate differences across these studies carry nuances reflecting their protocol designs, the foundational consensus principles established in clinical guidelines and contemporary practice are as follows:

• CHAP compared a strategy of treating mild chronic hypertension to below 140/90 mm Hg with an approach of withholding treatment unless blood pressure reached the severe range.
• Since the publication of this trial, the American College of Obstetricians and Gynecologists (ACOG) has adopted 140/90 mm Hg as the threshold for initiating or titrating therapy in pregnant women with chronic hypertension.
• The CHIPS trial, which evaluated a target diastolic blood pressure of 85 mm Hg versus 100 mm Hg, forms the basis for the tighter targets adopted by the ISSHP and Canadian guidelines.

The primary clinical reassurance provided by this expanded body of evidence within guidelines and expert consensus is that controlled reduction of non-severe blood pressure does not significantly increase the risk of small-for-gestational-age (SGA) birth. Historically, the primary hesitation justifying permissive management was precisely this concern regarding fetal growth restriction.

Gestational Hypertension and Preeclampsia Without Severe Features: An Unresolved Threshold

Guideline positions diverge regarding gestational hypertension and preeclampsia without severe features. A 2025 review argued against oral antihypertensive treatment in this patient cohort, noting that hypertensive disorders affect approximately 13% of pregnancies and that ACOG does not recommend antihypertensive therapy for blood pressure below 160/110 mm Hg in either condition. The College justifies this stance by citing the absence of level 1 evidence, the risk of masking disease progression, and theoretical concerns regarding fetal growth restriction. The same authors cautioned that extrapolating CHAP results to these populations represents “indication creep” beyond proven clinical benefit^[7].

The counterargument contends that the maternal vasculature does not distinguish between chronic and gestational hypertension. The ISSHP and the UK National Institute for Health and Care Excellence (NICE) recommend initiating therapy at a 140/90 mm Hg threshold and targeting approximately 135/85 mm Hg, irrespective of hypertensive phenotype. Until a dedicated randomized trial settles the issue, both approaches remain defensible, provided that laboratory and fetal surveillance are not relaxed in treated patients. The masking argument holds validity only if lowered blood pressure is permitted to substitute for laboratory monitoring.

Aspirin Prophylaxis: Aggregate Evidence and the USPSTF Framework

The current US approach to aspirin prophylaxis is based on the updated evidence report and systematic review conducted by Henderson and colleagues for the US Preventive Services Task Force (USPSTF)^[8]. On this foundation, the Task Force recommends low-dose aspirin at 81 mg/day after 12 weeks of gestation for women at high risk of preeclampsia. Comprehensive meta-analyses and international guidelines (ISSHP/FIGO) indicate that placental benefit and the prevention of preterm preeclampsia are maximized when therapy is initiated specifically before 16 weeks.

The ISSHP and FIGO recommend a dose of 150 mg nightly, provided it is initiated before 16 weeks, and advise discontinuation at 36 weeks. NICE permits 75 to 150 mg daily from 12 weeks until delivery.

Dose Comparison: 150–162 mg Versus 75–81 mg

The most direct evidence regarding dosing stems from a meta-analysis restricted to randomized trials directly comparing these two regimens head-to-head, both initiated in the first trimester. Across four trials comprising 552 participants, the higher dose demonstrated the following:

• A reduction in the risk of preterm preeclampsia was achieved (three trials, 472 participants; relative risk 0.34, 95% CI 0.15 – 0.79, p value = 0.01, I2 0%).
• The risk of severe preeclampsia was also reduced (relative risk 0.23, 95% CI 0.09 – 0.62, p value = 0.003).
• No significant effect was detected on term preeclampsia (relative risk 0.57, 95% CI 0.12 – 2.64).
• When all preeclampsia cases were evaluated, only a borderline, non-statistically significant trend was observed (relative risk 0.42, 95% CI 0.17 – 1.05, p value = 0.06)^[9].

The authors acknowledged that the trials were small-scale and carried a heterogeneous risk of bias; hence, while directionally compelling, these findings are statistically fragile. Nonetheless, the distribution pattern of benefit is biologically coherent, concentrating in placentation-driven phenotypes—namely preterm and severe disease—where near-total thromboxane suppression is most critical.

Multiple Gestation

While twin gestation is considered a standalone high-risk indication warranting immediate initiation of aspirin in US guidelines (ACOG/USPSTF), the UK (NICE) guideline classifies it as a moderate risk factor requiring the presence of an additional risk factor. In a systematic review of nine studies encompassing a total of 2,273 twin pregnancies, the following findings were reported:

• Aspirin use was overall associated with lower odds of preeclampsia (odds ratio [OR] 0.64, 95% CI 0.48 – 0.85, p value = 0.003).
• This association was more pronounced in studies using doses above 100 mg/day (odds ratio 0.45, 95% CI 0.23 – 0.86, p value = 0.02).
• Studies evaluating doses above 80 mg/day showed no significant benefit.
• No significant differences were observed in gestational hypertension, fetal growth restriction, gestational age at delivery, or composite adverse maternal and perinatal outcomes.

According to GRADE methodology, the certainty of evidence for these findings was rated as low^[10]. Because twin gestation combines greater placental mass, higher sFlt-1 production, and more pronounced plasma volume expansion, it provides a biologically plausible rationale that the 81 mg dose is insufficient. However, this remains a rational deduction rather than an established fact.

Postpartum Blood Pressure Optimization: The POP-HT Imaging Substudy

Randomized evidence regarding the postpartum period is now increasingly emerging. In the POP-HT trial, women with hypertensive pregnancies were randomized to one of two arms:

• telemonitored self-management with physician-guided titration;
• usual postpartum care.

In an MRI substudy comprising 157 participants, 63% of whom were diagnosed with preeclampsia, brain volumes were evaluated at approximately 9 months postpartum. Total white matter volume was found to be better preserved in the intervention group, with an adjusted mean difference of 11.50 cm3 (95% CI 2.04 – 20.96, p value = 0.02). In the standard care arm, preeclamptic women exhibited smaller putamen volumes compared with women with gestational hypertension (adjusted difference minus 0.83 cm3, 95% CI minus 1.20 – minus 0.46, p value < 0.001). A similar pattern was also observed for the accumbens and pallidum, yet none of these differences were detected in the intervention arm^[11].

Brain volume is a surrogate endpoint, and these are secondary endpoints. Nevertheless, this finding supports the view that the weeks following delivery represent not a passive recovery phase, but a critical window of opportunity in which vascular damage can be modified.

Practical Implications and Safety Profile

Phenotypic Boundaries and Diagnostic Criteria

Accurate classification dictates the treatment threshold, therapeutic target, and monitoring intensity. For all diagnoses, blood pressure must be measured with a validated device, using an appropriately sized cuff, and with the patient in a seated position after a period of rest. Mild-to-moderate blood pressure elevations (140–159 / 90–109 mm Hg) must be confirmed by two separate measurements taken at least 4 hours apart; however, in severe-range measurements of 160/110 mm Hg or higher, treatment must not be delayed, and the diagnosis should be confirmed within minutes (15 minutes apart). The diagnostic categories are as follows:

• Chronic hypertension: Hypertension documented before pregnancy or prior to 20 weeks of gestation.
• Gestational hypertension: New-onset hypertension after 20 weeks of gestation in the absence of proteinuria or end-organ dysfunction.
• Preeclampsia: New-onset hypertension after 20 weeks of gestation accompanied by at least one of the following:
  • proteinuria (300 mg or greater in 24 hours, or a urine protein-to-creatinine ratio of 0.3 mg/mg or greater);
  • a platelet count below 100,000 per microliter;
  • a serum creatinine level above 1.1 mg/dL or a doubling of the baseline value;
  • elevation of transaminases to at least twice the upper limit of normal;
  • pulmonary edema;
  • new-onset cerebral or visual symptoms.

  The ISSHP also recognizes evidence of uteroplacental dysfunction, such as fetal growth restriction, as a defining criterion.

• Preeclampsia superimposed on chronic hypertension: A sudden refractory rise in blood pressure, new-onset proteinuria after 20 weeks of gestation in a woman previously without proteinuria, substantial worsening of preexisting proteinuria, or the emergence of new signs of maternal end-organ dysfunction independent of blood pressure control in a pregnant woman with chronic hypertension.
• Severe features: Persistent blood pressure elevations of 160/110 mm Hg or higher, or the presence of any sign of maternal end-organ involvement, such as thrombocytopenia (< 100,000/µL), hepatic dysfunction, renal failure, pulmonary edema, or persistent cerebral/visual symptoms unresponsive to analgesics and not accounted for by alternative diagnoses (the presence or degree of proteinuria alone is not considered a severe feature).

When the phenotype is indeterminate, angiogenic biomarkers provide guidance. In suspected preeclampsia between 20 and 37 weeks of gestation, an sFlt-1/PlGF ratio of 38 or lower has a high negative predictive value for ruling out the development of the disease within 1 week. Conversely, higher ratios exceeding 85, particularly before 34 weeks, indicate an imminent high risk. The availability of testing and precise cut-off values vary by platform and geographic region.

Aspirin: Candidate Selection, Dosing, and Timing

Aspirin should be initiated in women with any of the following high-risk factors:

• a history of preeclampsia in a prior pregnancy;
• multifetal gestation;
• chronic hypertension;
• pregestational type 1 or type 2 diabetes;
• chronic kidney disease;
• systemic lupus erythematosus or antiphospholipid syndrome.

In addition, prophylaxis should be recommended for women with two or more of the following moderate-risk factors:

• nulliparity;
• body mass index exceeding 30 kg/m2;
• a family history of preeclampsia;
• age 35 years or older;
• conception via in vitro fertilization;
• a history of adverse pregnancy outcomes or an interpregnancy interval exceeding 10 years;
• Black race, as a factor reflecting structural and social determinants of health;
• low socioeconomic status.

Where available, first-trimester combined screening enhances diagnostic performance in identifying women at risk for preterm preeclampsia. This screening model integrates maternal factors, mean arterial pressure, the uterine artery pulsatility index, and PlGF levels.

Aspirin should be initiated between 12 and 16 weeks of gestation and taken at bedtime. When risk is recognized late, starting therapy up to 28 weeks remains a reasonable approach, although the accrued benefit is attenuated. Whether the optimal dose is 81 mg or 150 to 162 mg remains controversial. The position advocating retention of the 81 mg dose argues that high-quality evidence justifying a higher dose remains insufficient^[12]. This question was revisited in a 2025 evaluation of the study by Kupka and colleagues on prophylactic aspirin dosing and preeclampsia^[13].

As a practical approach, a dose of 150 to 162 mg/day—administered as two 81-mg tablets in US formulations—is preferentially recommended in the following patient populations:

• women with obesity;
• women with twin gestations;
• those with a history of early-onset preeclampsia;
• women identified as high risk for preterm preeclampsia on screening.

For other women, the 81-mg dose remains an option aligned with United States guidelines. Aspirin should be discontinued at 36 weeks or at delivery, in accordance with local protocols. Care should be coordinated proactively with the anesthesia team; low-dose aspirin monotherapy does not constitute a contraindication to neuraxial anesthesia.

Bleeding Safety

The primary safety concern associated with higher doses is placental abruption and antepartum hemorrhage. A meta-analysis comprising 20 trials with a total of 12,585 participants evaluated this risk:

• At doses below 100 mg/day, aspirin demonstrated no significant effect on placental abruption or antepartum hemorrhage, whether initiated at or before 16 weeks (relative risk, 1.11; 95% CI, 0.52–2.36) or later (relative risk, 1.32; 95% CI, 0.73–2.39).
• At doses of 100 mg/day and higher, neither timing-stratified subgroup achieved statistical significance individually. When initiated at or before 16 weeks, the relative risk was 0.62 (95% CI, 0.31–1.26), whereas initiation after 16 weeks yielded a relative risk of 2.08 (95% CI, 0.86–5.06). The difference between these two subgroups was statistically significant (p value = 0.04)^[14].

The practical clinical takeaway is that high-dose aspirin must be initiated early. The scenario warranting genuine caution is commencing high doses in later stages of pregnancy.

Other contraindications include:

• aspirin-exacerbated respiratory disease;
• active peptic ulceration;
• known bleeding diatheses;
• true salicylate allergy.

Concurrent NSAID use should be avoided during aspirin therapy.

Oral Antihypertensive Protocols in Non-Severe Hypertension

First-line agents include:

• Labetalol: Initiated at 100 to 200 mg twice daily and titrated every 2 to 3 days to 200 to 400 mg twice or three times daily. The maximum dose is 2,400 mg/day. Because pregnancy shortens the half-life of the drug, three-times-daily dosing is frequently required.
• Extended-release nifedipine: Initiated at 30 mg once daily; titrated first to 60 mg, then to 90 to 120 mg/day as a single daily dose or in divided doses.

In the hyperdynamic phenotype and in the presence of tachycardia, labetalol is the logical first choice. In asthma or when a high vascular resistance profile is suspected, nifedipine is preferred.

Second-line options include:

• methyldopa, initiated at 250 mg two to three times daily and titrated up to 3 g/day;
• combination therapy with labetalol and nifedipine;
• oral hydralazine, initiated at 10 mg four times daily and titrated up to 200 mg/day, reserved as a third agent.

Thiazide diuretics may be continued in women with chronic hypertension who conceive while taking these medications. However, they should not be newly initiated in preeclampsia, a state characterized by contracted intravascular volume.

Blood pressure targets are a systolic pressure of 110 to 140 mm Hg and a diastolic pressure of approximately 85 mm Hg. If diastolic pressure drops below 80 mm Hg, the dose should be reduced.

In women taking RAAS inhibitors when pregnancy is diagnosed, medications must be switched immediately. First-trimester exposure alone does not constitute an indication for termination of pregnancy; however, it warrants detailed anatomical ultrasonography. Preconception counseling should be provided to women of reproductive age who are taking these agents.

Acute Severe Hypertension

Blood pressure values of 160 mm Hg systolic or 110 mm Hg diastolic persisting for 15 minutes mandate first-line emergent treatment within 30 to 60 minutes. Three options are available:

• Intravenous labetalol: Administered at 10-minute intervals—initially 20 mg, followed by 40 mg, then 80 mg—up to a cumulative maximum of 300 mg.
• Intravenous hydralazine: Administered at 5 to 10 mg every 20 minutes, up to a cumulative maximum of 20 to 30 mg.
• Short-acting oral nifedipine: Administered as 10 mg; if necessary, repeated as 20 mg after 20 minutes, and an additional 20 mg after another 20 minutes.

Oral nifedipine is particularly valuable when intravenous access is delayed. If target pressure is not achieved despite reaching the maximum dose of one agent, therapy should be switched to an alternative agent, and the critical care team should be involved.

Magnesium sulfate should be administered to women with preeclampsia with severe features:

• Administration regimen: An intravenous loading dose of 4 to 6 g over 15 to 20 minutes, followed by an infusion of 1 to 2 g/hour maintained for 24 hours postpartum.
• Clinical monitoring: Patellar reflexes, respiratory rate (the infusion must be discontinued if it drops below 12 breaths per minute), and urine output (at least 30 mL/hour) must be monitored.
• Serum levels: Serum magnesium levels should be monitored in the presence of renal impairment.
• Toxicity: Intravenous calcium gluconate, 1 g, serves as the antidote.

Co-administration of short-acting nifedipine with magnesium should be avoided in patients predisposed to hypotension, and patients should be closely monitored when these two agents are combined.

Laboratory Monitoring and Fetal Surveillance

The frequency of surveillance depends on the phenotype:

• Chronic hypertension: Baseline assessment of creatinine, electrolytes, liver enzymes, platelet count, urine protein-to-creatinine ratio, and an ECG should be performed in early pregnancy.
• Gestational hypertension and preeclampsia without severe features: Platelet counts, creatinine, and transaminases should be repeated weekly; blood pressure should be assessed at least twice weekly, including home measurements.
• Fetal surveillance: In chronic hypertension, fetal growth should be evaluated by ultrasonography every 3 to 4 weeks; in gestational hypertension or preeclampsia, ultrasound, amniotic fluid index, and umbilical artery Doppler velocimetry (when indicated) should be performed at diagnosis. Antenatal fetal surveillance should begin at diagnosis in high-risk cases or those with growth restriction, and no later than 32 weeks of gestation in stable presentations.

Regarding delivery timing, delivery at 37 weeks is recommended for gestational hypertension and preeclampsia without severe features. In preeclampsia with severe features, delivery should occur at 34 weeks, or earlier in the event of maternal or fetal clinical deterioration.

Postpartum Management

Blood pressure typically peaks between postpartum days 3 and 6. In women with severe hypertension, blood pressure must be evaluated within the first 72 hours postpartum, either inpatient or post-discharge; across all hypertensive pregnancies, reassessment should occur at 7 to 10 days postpartum. Persistent values of 150/100 mm Hg or higher should be treated. The primary agents compatible with breastfeeding include:

• nifedipine;
• labetalol;
• enalapril, particularly beneficial in the presence of proteinuria or pregestational diabetes;
• amlodipine.

Methyldopa should be discontinued postpartum and transitioned to an alternative agent because of its association with depression. The role of NSAID analgesia in postpartum hypertension remains debated; many centers utilize these agents cautiously in cases without severe disease.

Severe blood pressure elevations of ≥ 160/110 mm Hg or neurologic symptoms such as persistent headache and visual disturbances occurring up to 6 weeks postpartum warrant immediate emergency department evaluation for postpartum preeclampsia, and confirmed severe hypertension should be treated within 30 to 60 minutes. Milder symptoms necessitate same-day clinical assessment. These presentations should be managed with antihypertensives and magnesium sulfate, identical to antepartum protocols, with diuretic therapy instituted when evidence of volume overload is present.

Future Perspectives and Open Questions

From a clinical standpoint, the most critical and unresolved question is whether lowering blood pressure to a target of 140/90 mm Hg in gestational hypertension and preeclampsia without severe features improves clinical outcomes. Similarly, whether such treatment delays recognition of disease progression or adversely affects fetal growth remains unclear. This necessitates an adequately powered, independent randomized controlled trial with prespecified fetal growth and neurodevelopmental endpoints. Extrapolation from chronic hypertension data cannot answer this question.

A related question is whether hemodynamically guided agent selection—matching beta-blockers to high-cardiac-output states and vasodilators to high-resistance states—confers superiority over empirical treatment. Resolving this question will require noninvasive cardiac output monitoring to become routine practice in antenatal clinics.

The principal unanswered questions regarding aspirin include:

• whether the 150–162 mg dose should universally replace 81 mg or remain restricted to phenotypes at risk for underdosing, such as obesity and twin gestations;
• whether aspirin can be safely discontinued before 36 weeks of gestation in women with normal angiogenic profiles;
• whether bedtime dosing confers an incremental chronotherapeutic benefit beyond treatment adherence;
• how to define and manage true aspirin non-responsiveness through platelet function testing or empirical dose escalation.

Elemental calcium supplementation of 1.5 to 2 g/day is recommended by the World Health Organization for populations with low dietary calcium intake. However, its clinical value in calcium-replete populations remains uncertain, and lower-dose regimens are currently under evaluation.

Several therapeutic candidates are currently under investigation and development:

• Pravastatin: Upregulates heme oxygenase-1 and PlGF while decreasing sFlt-1 levels.
• Metformin: Reduces sFlt-1 and soluble endoglin secretion in experimental models and exerts mitochondrial effects.
• Proton pump inhibitors.
• Therapeutic sFlt-1 apheresis.
• Silencing of placental sFlt-1 via small interfering RNA (siRNA): Has demonstrated promising results in non-human primate models.

None of these approaches has yet demonstrated reproducible clinical benefit in adequately powered human trials. Although the previously summarized in vitro trophoblast data support this drug repurposing strategy, they cannot substitute for clinical evidence.

Finally, the existing evidence base exhibits notable structural limitations:

• trials underrepresent Black women, who experience the highest case-fatality rates;
• most aspirin dose comparisons are small and heterogeneous;
• most postpartum interventions report surrogate endpoints rather than hard clinical outcomes.

Emerging data from postpartum remote monitoring trials point to a cardiovascular trajectory that originates in pregnancy and persists across the lifespan. This topic is addressed in detail in Part 2 of our review.

References

1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(16):1661-1667. doi:10.1001/jama.2017.3439. PubMed
2. Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2022;226(2S):S1211-S1221. doi:10.1016/j.ajog.2020.10.027. PubMed
3. Jones Pullins ME, Boggess KA. Aspirin dosage for preeclampsia prophylaxis: an argument for 162-mg dosing. Am J Obstet Gynecol MFM. 2025;7(1S):101620. doi:10.1016/j.ajogmf.2025.101620. PubMed
4. Afrose D, Alfonso-Sánchez S, Philp A, Hansbro PM, Su QP, McClements L. Targeting trophoblast cell mitochondrial dysfunction in preeclampsia via drug repurposing. Chem Biol Interact. 2026;424:111883. doi:10.1016/j.cbi.2025.111883. PubMed
5. Tatapudi R, Pasumarthy LR. Maternal cardiac function in gestational hypertension, mild and severe preeclampsia and normal pregnancy: A comparative study. Pregnancy Hypertens. 2017;10:238-241. doi:10.1016/j.preghy.2017.10.004. PubMed
6. Leeson P. Chronic Hypertension in Pregnancy Project and the Control of Hypertension in Pregnancy Study: impact of blood pressure control in pregnancy on maternal and fetal outcomes. Cardiovasc Res. 2022;118(14):e98-e100. doi:10.1093/cvr/cvac147. PubMed
7. Griffin LB, Sinkey R, Tita A, Rouse DJ. Nonsevere hypertensive disorders of pregnancy and oral antihypertensive medications: an argument against use. Am J Obstet Gynecol MFM. 2025;7(1S):101560. doi:10.1016/j.ajogmf.2024.101560. PubMed
8. [Yazar bilgisi yok]. More evidence for low-dose aspirin in preventing pre-eclampsia. Drug Ther Bull. 2022;60(2):19. doi:10.1136/dtb.2021.000071. PubMed
9. Ghesquiere L, Guerby P, Marchant I, Kumar N, Zare M, Foisy MA, et al. Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(7):101000. doi:10.1016/j.ajogmf.2023.101000. PubMed
10. D’Antonio F, Khalil A, Rizzo G, Fichera A, Herrera M, Buca D, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(2):100803. doi:10.1016/j.ajogmf.2022.100803. PubMed
11. Lapidaire W, Kitt J, Krasner S, Bateman PA, Cutler HR, Barr L, et al. Brain Volumes After Hypertensive Pregnancy and Postpartum Blood Pressure Management: A POP-HT Randomized Clinical Trial Imaging Substudy. JAMA Neurol. 2026;83(2):137-144. doi:10.1001/jamaneurol.2025.5145. PubMed
12. Balhotra KS, Sibai BM. Aspirin dosage for preeclampsia prophylaxis: an argument for 81-mg dosing. Am J Obstet Gynecol MFM. 2025;7(1S):101568. doi:10.1016/j.ajogmf.2024.101568. PubMed
13. [Yazar bilgisi yok]. What dose of aspirin for preventing pre-eclampsia?. Drug Ther Bull. 2025;63(11):165. doi:10.1136/dtb.2025.000029. PubMed
14. Roberge S, Bujold E, Nicolaides KH. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol. 2018;218(5):483-489. doi:10.1016/j.ajog.2017.12.238. PubMed

Share this article

LinkedIn X Facebook WhatsApp Copy Link